24
Participants
Start Date
August 27, 2018
Primary Completion Date
February 2, 2024
Study Completion Date
February 2, 2024
Gemcitabine
Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).
Nab-paclitaxel
Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
Chilldren's Healthcare of Atlanta, Atlanta
Johns Hopkins All Children's Hospital, St. Petersburg
Children's Mercy Hospital, Kansas City
Children's Hospital Colorado, Aurora
Collaborators (1)
Celgene Corporation
INDUSTRY
Emory University
OTHER